PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397264
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397264
The global molecular transport medium market, which recorded revenues of US$ 1.6 billion in 2021, experienced a temporary dip but is now poised for steady growth. Projections indicate the market reaching US$ 1.2 billion by 2031.
Technological advancements have led to a shift from traditional transport mediums to innovative molecular transport mediums, offering enhanced safety and convenience. These new products reduce exposure risks with non-hazardous and leak-proof formulations for transport, storage, and processing.
Preserving sample stability during transport and storage is another critical driver, as rapid storage is vital to prevent degradation or cell death after sample collection. Molecular transport mediums play a crucial role in maintaining sample stability during storage and transportation for approximately 48 hours, avoiding the need for freezing and thawing.
Alternative solutions for stabilizing specimens, particularly for virus, bacteria, and fungus detection, pose a challenge to the molecular transport medium market. These solutions often use saline or buffered salt solutions to maintain a neutral pH. Researchers are exploring plant-based protein supplements to enhance virus stability.
Seasonal infections and the unpredictability of disease outbreaks affect demand for molecular transport mediums. Public awareness campaigns have increased testing rates, but demand may still outstrip supply due to the sporadic nature of infections.
Shelf-life limitations also hinder market growth, as molecular transport mediums have a short storage duration.
High awareness of disease prevention benefits, the presence of key players, and increased healthcare expenditure drive the demand for molecular transport mediums in the U.S.
The launch of novel viral transport mediums, such as Thermo Fisher Scientific Inc.'s InhibiSURE, has boosted sales in European countries, including Germany, by ensuring rapid inactivation of the COVID-19 virus during collection and transport.
Major government investments have prompted manufacturers to increase production capacity to meet surging demand for comprehensive testing of symptomatic and asymptomatic patients, driven by COVID-19 and other infectious diseases.
India's focus on genetic research and innovative product development for biological sample storage and transport, exemplified by Azooka Labs' mWRAPR, has fueled market growth. mWRAPR, India's first local biological storage and transport medium, has garnered support from institutions like Honeywell and Citigroup.
Leading market players are expanding their production capacities to meet high demand during peak periods and offering competitive pricing. They are also developing advanced products to attract more end-users and increase market share.